🍽️ (s)-(-)-cycloserine (antibiotic)

AI Engines For more Details: PerplexityKagi LabsYou

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of (s)-(-)-cycloserine (antibiotic) On Probiotics

Rank Probiotic Impact

Bacteria Impacted by (s)-(-)-cycloserine (antibiotic)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Bacteroides genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of (s)-(-)-cycloserine (antibiotic) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.5 0.5
ADHD 0.1 0.1
Age-Related Macular Degeneration and Glaucoma 0.1 -0.1
Allergic Rhinitis (Hay Fever) 0.3 0.3
Allergy to milk products 0.2 0.1 1
Alopecia (Hair Loss) 0.1 0.1
Alzheimer's disease 0.7 1.5 -1.14
Ankylosing spondylitis 0.1 0.2 -1
Anorexia Nervosa 0.1 0.2 -1
Antiphospholipid syndrome (APS) 0.5 -0.5
Asthma 0.2 -0.2
Atrial fibrillation 0.3 0.8 -1.67
Autism 0.5 0.8 -0.6
Bipolar Disorder 0.8 0.8
Brain Trauma 0.2 -0.2
Carcinoma 0.8 0.3 1.67
Celiac Disease 0.2 0.8 -3
Cerebral Palsy 0.2 -0.2
Chronic Fatigue Syndrome 0.3 0.3 0
Chronic Kidney Disease 0.5 0.5
Chronic Lyme 0.2 -0.2
Coagulation / Micro clot triggering bacteria 0.1 0.1
Colorectal Cancer 0.3 0.3
Constipation 0.2 0.2
COVID-19 0.3 0.6 -1
Crohn's Disease 0.8 0.3 1.67
cystic fibrosis 0.2 -0.2
Depression 1.2 0.3 3
Endometriosis 0.3 0.3
Epilepsy 0.2 0.3 -0.5
Fibromyalgia 0.1 0.2 -1
Functional constipation / chronic idiopathic constipation 0.3 0.9 -2
gallstone disease (gsd) 0.1 0.1
Generalized anxiety disorder 0.2 -0.2
Graves' disease 0.3 0.3
Halitosis 0.2 0.2
Hashimoto's thyroiditis 0.5 0.7 -0.4
Hidradenitis Suppurativa 0.5 0.5
Histamine Issues,Mast Cell Issue, DAO Insufficiency 0.2 0.1 1
hyperglycemia 0.3 -0.3
hypersomnia 0.5 -0.5
hypertension (High Blood Pressure 0.3 0.7 -1.33
Hypoxia 0.3 0.3
Inflammatory Bowel Disease 0.2 0.3 -0.5
Insomnia 0.2 0.2 0
Intracranial aneurysms 0.3 0.3
Irritable Bowel Syndrome 0.6 0.3 1
Liver Cirrhosis 0.8 0.7 0.14
Long COVID 0.7 0.8 -0.14
Lung Cancer 0.4 0.4
ME/CFS with IBS 0.2 -0.2
ME/CFS without IBS 0.1 0.3 -2
Metabolic Syndrome 1.2 0.8 0.5
Mood Disorders 1.7 0.3 4.67
Multiple Sclerosis 0.6 0.4 0.5
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.2 -0.2
Obesity 1.5 0.3 4
obsessive-compulsive disorder 0.3 0.5 -0.67
Osteoarthritis 0.2 0.2
Osteoporosis 0.2 0.2 0
Parkinson's Disease 0.6 0.6
Polycystic ovary syndrome 0.3 0.3
Premenstrual dysphoric disorder 0.1 -0.1
Psoriasis 0.4 -0.4
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.8 0.2 3
Rosacea 0.2 0.2
Schizophrenia 0.8 0.8
scoliosis 0.5 -0.5
Sjögren syndrome 0.1 0.3 -2
Sleep Apnea 0.2 -0.2
Stress / posttraumatic stress disorder 0.3 0.2 0.5
Systemic Lupus Erythematosus 0.8 0.8
Tourette syndrome 0.2 -0.2
Type 1 Diabetes 0.7 0.7
Type 2 Diabetes 1.2 0.3 3
Ulcerative colitis 0.2 0.8 -3
Unhealthy Ageing 1 1

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.


The awesome web hosting site that we use. Try it if you need to host (or unhappy with current provider)